Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ixchelsis Ltd.

ixchelsis.com

Latest From Ixchelsis Ltd.

Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding

With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.

Deals Financing

The A-List: The Trend-Shaping Series A Financings Of 2013

It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.

BioPharmaceutical Medical Device

Crescendo Biologics Raises $28M To Develop Fully Human Antibody-Fragment Technology

The U.K. biotech aims to transform the biologics market with its first-in-class human antibody-fragment technology, with mild to moderate psoriasis the lead therapeutic target.

BioPharmaceutical United Kingdom

Lilly’s Venture Strategy Matures As PoC Data Catalysts Approach

As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ixchelsis Ltd.
  • Senior Management
  • Gary Muirhead, CEO
    Ian Osterloh, CMO
  • Contact Info
  • Ixchelsis Ltd.
    Discovery Park House
    Ramsgate Rd.
    Sandwich, CT13 9NJ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register